Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Lecture outline (1)
- Jean Martin Charcot, 1825-1893
- Motor neurons (1)
- Motor neurons (2)
- Motor Neuron Disease / Amyotrophic Lateral Sclerosis
- SOD1 is the first identified genetic cause of MND
- SOD1 mutations
- SOD1 mutations: toxic gain of function of mutant protein
- MND genetic epidemiology
- Frequency of SOD1 mutations
- Autosomal dominant inheritance
- ALS / MND is a heterogeneous condition
- Genetic heterogeneity of ALS / MND
- Clinical heterogeneity of MND
- Clinical features specific to SOD-ALS / MND
- Features of specific SOD1 mutations
- Pathological heterogeneity
- Pathological heterogeneity of MND
- Lecture outline (2)
- Cu / Zn SOD1 gene and protein
- The SOD1 protein is a constitutively expressed powerful antioxidant enzyme
- SOD1 acts as a superoxide dismutase
- Over 180 ALS-causative mutations in SOD1 are known
- Lecture outline (3)
- Identification of the SOD1 gene allowed MND disease modelling
- All ALS models
- Transgenic mouse models
- Phenotypic characterisation of SOD1 mouse models
- G93A SOD1 transgenic mouse
- Zebrafish model of SOD1-MND
- Zebrafish models of MND
- Cellular reprogramming of skin cells to make motor neurons or astrocytes “in a dish”
- iNPCs are tripotent, non-clonal and retain the ageing phenotype
- Astrocytes made from fibroblasts of MND patients are toxic to motor neurons in co-culture
Topics Covered
- Motor neurons
- Amyotrophic Lateral Sclerosis (ALS)
- Motor Neuron Disease (MND)
- SOD1 gene
- Protein function of SOD1
- SOD1 mutations
- ALS / MND caused by SOD1 mutations
- Heterogeneity of ALS / MND
- Models of SOD1 related ALS / MND
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Shaw, P. (2022, May 30). SOD1-related ALS: what has it told us about motor neuron degeneration? - part 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 24, 2024, from https://doi.org/10.69645/HKJH4128.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dame Pamela Shaw has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
SOD1-related ALS: what has it told us about motor neuron degeneration? - part 1
Published on May 30, 2022
26 min
Other Talks in the Series: ALS and Other Motor Neuron Disorders
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Professor
Dame Pamela Shaw.
I'm a professor of neurology
and Director of the
Sheffield Institute for
Translational
Neuroscience (SITraN)
at the University of
Sheffield in the UK.
My lecture is going to discuss
a form of Motor
Neuron Disease or
Amyotrophic Lateral
Sclerosis (ALS) related to
mutations in the SOD1 gene.
I'm going to talk about
what work on SOD1 gene
has told us about motor
neuron degeneration.
0:38
I have no disclosures
relevant to this lecture.
0:43
In the lecture, I'm going
to cover these six areas.
First of all, I'm going to
introduce Motor Neuron Disease,
which I will
summarise as ALS/MND.
Next, I will talk
about the SOD1 gene
and its encoded protein.
I will talk about the
models that have been
generated for
SOD1-related ALS/MND.
I'll then discuss the
mechanisms that we understand
about motor neuron injury in
the presence of SOD1 mutations.
I'll briefly talk
about determinants
of fast and slow
disease progression
and in the final section,
I will discuss
therapeutic approaches
for this sub-type of MND,
including gene
therapy approaches.
1:35
By way of introduction,
just to remind you,
the medical condition of ALS/MND
was first described by a
French physician known as
Jean-Martin Charcot at the
Salpêtrière Hospital in Paris,
and he described the
clinical and pathological
features of ALS/MND,
as far back as 1869.
Hide